Publications by authors named "Donald A Berry"

Claim this Profile
S
Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues.
Donald A Berry

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.
Donald A Berry

J Clin Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Annual Versus Biennial Mammographic Screening.
Donald A Berry

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace, Donald A Berry

Breast Cancer Res Treat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Michael J Campbell, Denise M Wolf, Christina Yau, Lamorna Brown-Swigart, Julie Wulfkuhle, Donald A Berry

Cell Rep Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Nathalie A Waser, Melanie Quintana, Bernd Schweikert, Jamie E Chaft, Lindsay Berry, Donald A Berry

JNCI Cancer Spectr· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, Scott Berry, Donald A Berry

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Breast Cancer Mortality in the US-1975 to 2019.
Jennifer L Caswell-Jin, Liyang P Sun, Diego Munoz, Ying Lu, Yisheng Li, Donald A Berry

JAMA· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.
Donald A Berry, Shobha Dhadda, Michio Kanekiyo, David Li, Chad J Swanson, Scott M Berry

JAMA Netw Open· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.
Kristine Broglio, Lale Kostakoglu, Carol Ward, Federico Mattiello, Denis Sahin, Donald A Berry

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
Nicholas J Short, Chenqi Fu, Donald A Berry, Roland B Walter, Sylvie D Freeman

Leukemia· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi, Minetta C Liu, Eric A Klein, Oliver Venn, Earl Hubbell, Donald A Berry

Cancer Cell· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, Scott Berry, Donald A Berry

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
Shobha Dhadda, Michio Kanekiyo, David Li, Chad J Swanson, Michael Irizarry, Scott Berry, Donald A Berry

Alzheimers Res Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials.
Benjamin R Saville, Donald A Berry, Nicholas S Berry, Kert Viele, Scott M Berry

Clin Trials· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Henry Hiep Vo, Siqing Fu, David S Hong, Daniel D Karp, Sarina Piha-Paul, Donald A Berry

NPJ Precis Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Donald A Berry

Cancer Cell· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Chad J Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Donald A Berry, Scott Berry

Alzheimers Res Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial.
Georgene W Hergenroeder, Shoji Yokobori, Huimahn Alex Choi, Karl Schmitt, Michelle A Detry, Donald A Berry

Neurocrit Care· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.
Merit E Cudkowicz, Stacy R Lindborg, Namita A Goyal, Robert G Miller, Matthew J Burford, James D Berry, Donald A Berry

Muscle Nerve· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
Kirit Singh, Kristen A Batich, Patrick Y Wen, Aaron C Tan, Stephen J Bagley, Donald A Berry

Clin Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Natsuko Onishi, Wen Li, David C Newitt, Roy J Harnish, Fredrik Strand, Donald A Berry

Radiology· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
W Fraser Symmans, Christina Yau, Yunn-Yi Chen, Ron Balassanian, Molly E Klein, Donald A Berry

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 breast cancer in the adaptively randomized I-SPY2 trial.
Amy S Clark, Christina Yau, Denise M Wolf, Emanuel F Petricoin, Laura J van 't Veer, Scott Berry, Donald A Berry

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Douglas Yee, Claudine Isaacs, Denise M Wolf, Christina Yau, Paul Haluska, Scott Berry, Donald A Berry

NPJ Breast Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis